EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Therapeutic vaccines targeting solid tumors: A series of clinical trial analysis over the past decade

Fengqi Qiu, Yilan Sun, Darren Wan-Teck Lim

Translational Oncology · 2026-08 · 70 · 102831

DOI: 10.1016/j.tranon.2026.102831 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-08. Verfasst von Fengqi Qiu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medi…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Medical Research Council, Medical Science and Technology Project of Zhejiang Province, Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic cancer vaccines hold great promise, yet their clinical efficacy in solid tumors remains modest. We systematically analyzed 86 clinical trials published between 2015 and 2025 evaluating therapeutic vaccines across mRNA, DNA, peptide, dendritic cell, virus vector, and whole tumor cell platforms to understand their clinical utility and key challenges in development. Peptide-based vaccines dominated, while mRNA vaccines showed the fastest growth, often combined with immune checkpoint inhibitors. Among 1588 patients with advanced disease, the disease control rate was 53 % and the objective response rate 18 %. In adjuvant settings, 52 % of 461 patients experienced recurrence. Although 67 % exhibited ELISPOT-positive T-cell responses, no correlation with clinical efficacy was observed. Most adverse events were mild to moderate, with pyrexia, fatigue, and injection-site reactions predominating. Therapeutic vaccines thus demonstrate favorable safety and immunogenicity, but limited monotherapy efficacy, underscoring the need for combinatorial approaches and identifying personalized immunogenic neoantigens to enhance clinical benefit.

Schlagwörter

Stichwörter der Autor:innen

Cancer vaccineImmunotherapyPersonalized neoantigensSolid tumorT-cell response

Autor:innen und Institutionen

  • Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China; National Cancer Centre Singapo…
  • Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address: sunylhz197…
  • National Cancer Centre Singapore, Singapore, Singapore; Duke-NUS Medical School, Singapore, Singapore. Electronic address: darren.lim.w.t@singhealth.com.sg.

Förderung

  • National Medical Research Council
  • Medical Science and Technology Project of Zhejiang Province
  • Zhejiang Province Natural Science Foundation
  • Naval Medical Research Command

Zitieren

APA

Qiu, F., Sun, Y., & Lim, D. W. (2026). Therapeutic vaccines targeting solid tumors: A series of clinical trial analysis over the past decade. Translational Oncology, 70, 102831. https://doi.org/10.1016/j.tranon.2026.102831

Vancouver

Qiu F, Sun Y, Lim DW. Therapeutic vaccines targeting solid tumors: A series of clinical trial analysis over the past decade. Translational Oncology. 2026;70:102831. doi:10.1016/j.tranon.2026.102831

BibTeX
@article{Qiu2026,
  author = {Qiu, Fengqi and Sun, Yilan and Lim, Darren Wan-Teck},
  title = {Therapeutic vaccines targeting solid tumors: A series of clinical trial analysis over the past decade},
  journal = {Translational Oncology},
  year = {2026},
  volume = {70},
  pages = {102831},
  doi = {10.1016/j.tranon.2026.102831}
}
Kostenlos starten →